Cipla reported a 54.6% year-on-year declined in its consolidated net profit to Rs 554.64 crore in Q4FY26 from Rs 1,221.84 crore reported in Q4FY25.
Total revenue from operations stood at Rs 6,541.20 crore in Q4FY26, down 2.80% from Rs 6,729.69 crore reported in Q4FY25.
“One India” sales were at Rs 3,007 crore in Q4FY26, up 15% from Rs 2,622 crore reported in Q4FY25.
| Q4FY26 | Q4FY25 | YoY Change | |
|---|---|---|---|
| Net profit | Rs 554.64 crore | Rs 1,221.84 crore | ↓ 54.6% |
| Revenue | Rs 6,541.20 crore | Rs 6,729.69 crore | ↓ 2.80% |
| One India sales | Rs 3,007 crore | Rs 2,622 crore | ↑ 15% |
Rs 13 dividend announced
Cipla has recommended a final dividend of Rs 13 per equity share for FY26. If approved by shareholders at the Annual General Meeting (AGM), the dividend will be paid within 30 days of the meeting. The record date to determine eligible shareholders is June 5.
FY26 highlights
For the full financial year of FY26, Cipla’s net profit falls 26.71% to Rs 3,861.74 from Rs 5,269.20 crore reported in FY25
FY26 revenue rose 2.23% to Rs 28,162.59 crore from Rs 27,547.62 crore reported in FY25.
Achin Gupta, MD and Global CEO of Cipla said that the company recorded its highest-ever yearly revenue in FY26 reflecting the strength of the core businesses despite certain markets facing near-term challenges.
“Our One-India business surpassed the Rs 12,500 crore annual revenue milestone. Key therapies in branded prescription business delivered robust double-digit growth, trade generics business sustained the strong growth momentum and anchor brands of consumer health business maintained leadership position,” he added.
The US business posted an annual revenue of $780 million supported by demand in differentiated portfolios and a steady base business, Gupta said, adding that emerging markets and Europe crossed the $400 million annualised revenue threshold on the back of deep market focus strategy.
Going ahead, Gupta said, “The focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front.”
About Cipla
Cipla is India’s third-largest drugmaker by revenue. It is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.
During the quarter Cipla acquired 100% stake in Inzpera Healthscience Limited for Rs 110.65 crore in December 2025.
Cipla Share price
The share price of Cipla has gained 1.63% in the intraday session today. However, on year to date basis, Cipla shares has declined 11.9% so far this year.